Leaflet DIGIFAB 40mg powder infusion solution


Indicated for: cardiac arrhythmias

Route of administration: infusion

Substance: antidigoxin antibodies (antiarrhythmic)

ATC: V03AB24 (Various | All other therapeutic products | Antidotes)

Antidigoxin antibodies are used as an antidote for the treatment of digoxin toxicity, a condition that can occur following excessive administration of digoxin, a medication used for heart failure and arrhythmias. These antibodies specifically bind to digoxin molecules in the blood, forming complexes that are then eliminated by the kidneys, thereby reducing the toxic effects of digoxin.

Antidigoxin antibodies are administered intravenously, usually in emergency situations, with the dosage calculated based on the serum digoxin level and the patient's weight.

Common side effects include injection site reactions, nausea, fever, and hypokalemia. In rare cases, severe allergic reactions or renal failure may occur.

Patients receiving antidigoxin antibodies should be closely monitored for signs of adverse reactions and serum digoxin levels. This treatment is essential for managing severe digoxin toxicity, providing a rapid and effective solution to reduce the risk of serious complications.

General data about DIGIFAB 40mg

  • Substance: antidigoxin antibodies
  • Date of last drug list: 01-07-2023
  • Commercial code: W69597001
  • Concentration: 40mg
  • Pharmaceutical form: powder infusion solution
  • Quantity: 1
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: SERB - FRANTA
  • Holder: CN UNIFARM S.A. - ROMANIA
  • Number: 801/2023/01